Embecta Corp (NASDAQ: EMBC) is a medical device company focused on diabetes care that manufactures and sells drug delivery devices used by people living with diabetes. Revenue is generated through transactional product sales of injection and delivery devices distributed across global healthcare channels. Embecta was spun off from Becton, Dickinson and Company and operates as an independent company listed on the Nasdaq Global Select Market. The company serves an end market shaped by a growing global diabetic population and a secular shift in chronic care delivery from hospitals to primary care settings. As of September 30, 2025, Embecta held $228.6 million in cash and equivalents and restricted cash, generated $191.7 million in operating cash flow in FY2025, and carried net income of $95.4 million. The capital structure is debt-heavy, with $184.6 million in long-term debt payments made during FY2025. Credit ratings as of mid-2025 stand at B1 from Moody's and B+ from Standard and Poor's. The company declares dividends, with $35.0 million in dividend payments made during FY2025.

Revenue model

Transactional product sales of diabetes drug delivery devices sold through healthcare distribution channels globally.

Products and services

Diabetes drug delivery devices including injection devices, subject to FDA regulation governing design, manufacturing, labeling, and distribution.

Customers and end markets

People living with diabetes and the healthcare providers serving them, including primary care providers. End market demand is driven by a growing and aging global diabetic population. Emerging markets represent a portion of the geographic footprint, with associated political and economic variability.

Value-chain role

Manufacturer and distributor of diabetes drug delivery devices, operating under FDA and international regulatory oversight across the full product lifecycle from development through post-market surveillance.

Geographic exposure

Global operations including the United States and multiple emerging markets. Subject to foreign regulatory requirements, data localization laws, and tariff exposure given international manufacturing and distribution footprint.

Source: SEC 10-K, filed 2025-11-25

Industry: Surgical & Medical Instruments & Apparatus Peers: Avanos Medical Inc Figs Inc Haemonetics Corp ICU Medical Inc MERIDIAN BIOSCIENCE INC Merit Medical Systems Inc Neogen Corp Silk Road Medical Inc STAAR Surgical Co